Caplan syndrome is caused by breathing in coal mining dust. This causes inflammation and can lead to the development of many small lung lumps (nodules) and mild asthma-like airway disease.
Some people who have been exposed to the dust have severe lung scarring that makes it difficult for their lungs to carry oxygen to the bloodstream (called progressive massive fibrosis). People with rheumatoid arthritis do not seem more likely to have this complication of scarring.
Caplan syndrome is very rare in the United States.
Your health care provider will take a detailed medical history that will include questions about your jobs (past and present) and other possible sources of exposure to mining dust. The health care provider will also do a physical exam, paying special attention to any joint and skin disease.
There is no specific treatment for Caplan syndrome, other than treating any lung and joint disease.
Attending support groups with other people who have similar diseases can help you understand your disease and adjust to its treatment and other lifestyle changes.
Caplan syndrome rarely causes serious breathing trouble or disability due to lung problems.
Increased risk for tuberculosis
Progressive massive fibrosis (scarring)
Side effects of medications
Calling your health care provider
Call for an appointment with your health care provider if you have symptoms of Caplan syndrome.
People with rheumatoid arthritis should avoid exposure to hazardous dust.
Corte TJ, duBois RM. The lungs and connective tissue diseases. In: Mason RJ, Broaddus VC, Martin TR, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 5th ed. Philadelphia, Pa: Saunders Elsevier; 2010:chap 58.
Cowie RL, Murray J, Becklake MR. Pneumoconioses and other mineral dust-related diseases. In: Mason RJ, Broaddus VC, Martin TR, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 5th ed. Philadelphia, Pa: Saunders Elsevier; 2010:chap 65.
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Denis Hadjiliadis, MD, Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care, University of Pennsylvania, Philadelphia, PA. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.